<p><strong>Tasty beer starts with knowing what’s in your hops. Explore how online SPE makes bitter acid analysis in hops faster and more reliable.</strong></p><h4><strong>How can you detect bitter acid profiles quickly, reliably, and more sustainably?</strong></h4><p>For craft brewers and beer lovers alike, a refreshing experience is all about flavor.</p><p>So how can you achieve the desired bitterness in your beer? The answer is not just about the recipe. Finding the right flavor profile starts with the bitter acids present in the starting hops material.</p><div><div><p>Hops (the heart of your favorite beer) are the source of the brew’s distinctive flavor tied to bitterness and aroma.</p><p>At the molecular level, bitterness is driven by <a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S0308814622016338">α- and β-bitter acids</a>, like humulones and lupulones, whose concentrations determine the final sensory profile of the beer (<strong>Figure 1</strong>).</p><p>Accurately characterizing these compounds in each batch allows brewers to unlock the full potential of every variety of hops.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 1. General chemical structure of hop bitter acids." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_2_6435757c03.jpeg 222w," sizes="100vw" width="700" height="493"></p><p>While conventional analytical methods rely on long, manual sample preparation steps and hazardous solvents, laboratories now strive for greener and more efficient workflows.</p><p>And moving from manual to online sample preparation is one of the easiest ways your lab can reduce waste and — most importantly — improve reliability with automation.</p><h4><strong>Key takeaways</strong></h4><ul><li>Online SPE reduces hands-on work, shortens turnaround time, and supports more sustainable methods by cutting solvent use and eliminating single-use cartridges.</li><li>Automated UHPLC workflows are easier for new users to execute, offering more reproducible quantifications of α- and β-bitter acids in hops.</li><li>Accurate bitter acid profiles help brewers distinguish hop varieties and control flavor with confidence.</li></ul><h4><strong>Comparing offline vs. online solid phase extraction for bitter acid HPLC analysis</strong></h4><p>If you’ve spent long hours in the lab preparing samples for hops analysis, you’re not alone.</p><p>Manual sample preparation often takes the most time in hops analysis, an area where online <a target="_blank" rel="noopener noreferrer" href="https://www.thermofisher.com/content/lifetech/global/en/home/industrial/chromatography/chromatography-learning-center/chromatography-consumables/sample-prep.html">solid phase extraction</a> (SPE) can make a real difference. Here’s why.</p><p>Manual SPE has a lot of manual steps. Extraction. Cartridge loading. Washing. Elution. And sometimes solvent exchange or reduction. All before your actual analysis begins. This labor-intensive workflow can take up to an hour and depends strongly on operator skillsets, making reproducibility a challenge for new hires.</p><h4><strong>Online SPE analysis provides key benefits like:</strong></h4><ul><li>Hands-off workflow free of cartridges, manifolds, or vacuum steps.</li><li>Column washing and re-equilibration occur in parallel with separation.</li><li>SPE step is complete in just two minutes.</li><li>Minimizes operator-dependent variability.</li><li>Uses less than 8 mL of solvent.</li></ul><p>Let’s explore what this technique looks like in practice.</p><h4><strong>Online SPE for analyzing α- and β-bitter acids in hops standard solutions.</strong></h4><p>Changing your sample preparation from manual to automated isn’t complicated. With the right tools you can fully integrate online SPE with your UHPLC system (<strong>Figure 2</strong>).</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 2. Schematic workflow for the determination of bitter acids in hops. The process involves clean up and instrumental analysis using the Thermo Scientific Vanquish Online SPE UHPLC System." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_3_4fb14243b4.jpeg 245w," sizes="100vw" width="700" height="323"></p><h4><strong>The process for analyzing a hops standard solution is straightforward:</strong></h4><ol><li>First, extract hop samples with ethanol (a greener alternative to toluene or diethyl ether in conventional methods).</li><li>Inject the extract directly into your instrument for analysis. Bitter acids retain<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/1970"><strong> on the SPE column</strong></a> while matrix interferences that can comprise quantitation are removed.</li><li>Next, backflush the SPE column to transfer the analytes to the<a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/423"><strong> analytical column </strong></a>for separation. While this separation is taking place, the SPE column is washed and re-equilibrated in parallel, keeping the total run time to 15 minutes, with the separation of all six major bitter acids in a single analysis (<strong>Figure 3</strong>).</li></ol><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 3. UV chromatogram of hop bitter acids in standard solution (1-cohumulone, 2-humulone, 3-adhumulone, 4-colupulone, 5-lupulone, 6-adlupulone)." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_4_1e47405e3c.jpeg 245w," sizes="100vw" width="700" height="347"></p><h4><strong>Online SPE for analyzing α- and β-bitter acids in real hops samples</strong></h4><p>Analytical labs need methods that are accurate and reliable for brewers to develop distinct and reproducible flavor profiles across batches.</p><p>To assess the applicability of online SPE UHPLC methods for hops analysis, we analyzed bitter acid profiles from four species — Sultana, Barbe Rouge, Azacca, and Sabro.</p><p>The concentration of α-acids dominated all samples, while each hops species exhibited distinct profiles in terms of α-acid and β-acid content, making them suitable for different brewing strategies (<strong>Figure 4</strong>).</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg" alt="Thermo Fisher Scientific: How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors: Figure 4. Bitter acid profiles in four different hop species, error bars display SD (n=6). To check method consistency, we measured each hops extract six times. Variation between measurements was low, with relative standard deviation below 3.5 % across all hops species." srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Thermo_Fisher_Scientific_How_Bitter_Acid_Analysis_Helps_Brewers_Better_Control_Beer_Flavors_5_3a179217db.jpeg 245w," sizes="100vw" width="700" height="410"></p><ul><li>For testing labs, this process translates into a workflow that is easy to run, fast, and delivers reliable results without added complexity.</li><li>For craft brewers, reliability means clear, trustworthy insights into hops bitter acid profiles, for better hop selection and more precise control of bitterness and flavor in your beer.</li></ul><h4><strong>From carefully procured samples to tasty sips</strong></h4><p>Efficient UHPLC workflows support faster results, less solvent use, and reliable bitterness data for brewers. And online SPE turns those advantages into practical, day-to-day benefits for brewers and labs alike.</p><ul><li>Less hands-on skills required for lab analysts</li><li>Faster results from labs to brewers</li><li>A more sustainable way to work</li><li>Clear insights into hops flavor</li></ul><p>To learn more about the method and see the full application data, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/labrulez-bucket-strapi-h3hsga3/cn_004238_hplc_vanquish_online_spe_bitter_acids_hops_cn004238_na_en_587a5d300b.pdf"><strong>check out our application note today</strong></a>.</p><h4><strong>FAQs</strong></h4><div><div><h5><strong>What are the key compounds in hops analyzed by HPLC?</strong></h5><p>Bitter acids, namely α-acids and β-acids, especially the six major bitter acids (humulones and lupulones) that define hop bitterness and are required for quality control and brewing decisions.</p></div><div><h5><strong>What column types are recommended for hop acid separations?</strong></h5><p>Classical C18 Silica columns are ideal for bitter acids separation. UHPLC compatible columns with particle size ≤ 2 µm boost analysis with higher flow rate, thus shorter analysis time and solvent consumption.</p></div><div><h5><strong>What’s the best workflow for hops analysis?</strong></h5><p>A typical workflow for hop analysis consists of three main steps: extraction of the target compounds, clean-up of co-extracted matrix components, and instrumental analysis by HPLC or UHPLC. To keep this workflow efficient and reproducible, you should minimize manual handling and add in automation when possible. Integrating online SPE into your LC instrument allows sample clean-up to run automatically, reducing hands-on time, solvent use, and variability while delivering faster, more reliable results.</p></div></div><blockquote><p><strong>Visit us on&nbsp;</strong><a target="_blank" rel="noopener noreferrer" href="https://www.linkedin.com/showcase/72003132/admin/dashboard/"><strong><u>LinkedIn:</u></strong></a>&nbsp;#UHPLC #Automation</p></blockquote></div></div>

How Bitter Acid Analysis Helps Brewers Better Control Beer Flavors

<p><strong>In the week of June 29, the following webinars await you in the field of liquid phase and especially HPLC and LC/MS.</strong></p><blockquote><h4><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinars"><strong>👉 DETAILS AND REGISTRATION IN THE WEBINARS SECTION</strong></a></h4><p><strong>👉 Search and filter in the largest global database</strong> with over <strong>5 500 GC, LC, MS and spectroscopy webinars</strong>.</p></blockquote><h5><strong>1. Thermo Fisher Scientific: Insights from an IC specialist: To be suppressed or not suppressed?</strong></h5><ul><li>Tu, 30.6.2026 09:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6310">Registration</a></li></ul><p>Join Thermo Fisher’s Ask the Experts session to learn how suppressor technology impacts ion chromatography performance, sensitivity, reliability, maintenance, and troubleshooting.</p><h5><strong>2. SCIEX: Advancing Proteomics with ZenoTOF: From Single-Cell Analysis to Plasma Biomarker Discovery</strong></h5><ul><li>Tu, 30.6.2026 11:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6311">Registration</a></li></ul><p>Discover how ZenoTOF high-resolution mass spectrometry is accelerating single-cell proteomics and plasma biomarker discovery through enhanced sensitivity, throughput, and automation.</p><h5><strong>3. Agilent Technologies: Measuring Diverse Samples with UV/VIS Spectrometers and Integrating Spheres</strong></h5><ul><li>Tu, 30.6.2026 20:30 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6052">Registration</a></li></ul><p>This webinar will discuss diffuse transmission and reflection UV/VIS measurements, including how to perform measurements with Agilent’s Cary 60 UV/VIS Spectrometer.</p><h5><strong>4. Waters Corporation: Informatics series #33 Tips, Tricks and Best Practices</strong></h5><ul><li>Th, 2.7.2026 11:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6315">Registration</a></li></ul><p>This interactive session revisits essential features, shortcuts, and practical techniques in Empower software that can streamline everyday laboratory work and reduce unnecessary effort.</p><h5><strong>5. Waters Corporation: Unlocking Therapeutic Peptide Characterisation (GLP-1RAs) with Cyclic IMS</strong></h5><ul><li>Th, 2.7.2026 15:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6313">Registration</a></li></ul><p>Discover how cyclic ion mobility spectrometry (cyclic IMS) improves characterization of GLP-1 analogues and therapeutic peptides, supporting development, quality control, and regulatory submissions.</p><h5><strong>6. Agilent Technologies: Spectral Flow Cytometry Masterclass - Session 1</strong></h5><ul><li>Fr, 3.7.2026 07:00 CEST</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/webinar/6316">Registration</a></li></ul><p>Learn how full-spectrum flow cytometry enables high-dimensional cell analysis. Explore spectral flow technology, experimental design, and applications in immunology, oncology, and vaccine research.</p>

Webinars LabRulezLCMS Week 27/2026

<p><strong>The international standard ISO/IEC 17025 [1] clause 7.7.2 with regards to ensuring the validity of results, requires a laboratory to participate in proficiency testing (PT) and/or to participate in interlaboratory comparisons (ILCs) other than PT. However, no guidance as to what these other ILCs might be, or indeed how they might compare in relation to PT, is provided. This leaflet aims to outline other ILCs available, pointing out some of the limitations as compared to PT.&nbsp;</strong></p><p>There are three major types of ILCs in which a group of laboratories analyses identical portions from a homogeneous, stable test sample, with each type being characterized by its intended purpose [2,3]:</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_2_d9263807fb.jpg 245w," sizes="100vw" width="1507" height="607"></p><p>A key point is that PT is an ILC that is designed to specifically evaluate the performance of participants, providing them with an infrastructure to monitor and assess the validity of their results. This is not the key purpose of the two other ILCs, and thus depending on their intended purpose they have a number of limitations that laboratories need to be aware of when using them rather than PT. Only proficiency testing should have been conducted in full compliance to the competency standard ISO/IEC 17043 [4].&nbsp;</p><h4><strong>Evaluation of measurement procedure performance&nbsp;</strong></h4><p>These ILCs, are designed to assess how a particular measurement procedure performs and whether it is fit for its intended purpose. These ILCs are often referred to as a ‘method performance study’ or a ‘collaborative study’ [2]. Some limitations of using such ILCs for monitoring laboratory performance as an alternative to PT are:&nbsp;</p><ul><li>All participants use the same measurement procedure i.e. the measurement procedure that is being validated. Unless the measurement procedure is being routinely used by the participating laboratory such an ILC will not assess the routine performance of the laboratory using their own routine measurement procedure. Nor does it enable them to compare their performance with other laboratories using alternative measurement procedures.&nbsp;</li><li>The measurement procedure is likely to be new, so participants may not have established stable procedures and quality control, so performance may not reflect routine use.&nbsp;</li><li>The report from such an ILC would not provide information on the performance of the participant, if the statistical model used makes the assumption that all laboratories perform with equal variability.</li><li>The design of the study may require the participants to assess multiple samples and/or to undertake multiple replicate analysis on the test materials. This may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li><li>The conclusion of the ILC might be that the measurement procedure being assessed is not valid.&nbsp;</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg" alt="Eurachem: Interlaboratory comparisons other than proficiency testing" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Eurachem_Interlaboratory_comparisons_other_than_proficiency_testing_3_a53ecd2f5d.jpg 157w," sizes="100vw" width="570" height="566"></p><h4><strong>Characterisation of candidate reference materials&nbsp;</strong></h4><p>These are ILCs that assign a property value to a candidate reference material, usually with a stated measurement uncertainty. These are often referred to as a ‘material certification study’ [2]. Limitations of using such ILCs as an alternative to PT are:&nbsp;</p><ul><li>The analysis of the candidate reference material is likely to require additional care in exercising the routine measurement procedure, such as substantially more replication, and/or may require quite different reporting formats (e.g. all valid replicates instead of a mean result). Thus, such an ILC will not necessarily provide an evaluation of the performance of the laboratory based on the routine use of their measurement procedures.&nbsp;</li><li>The report from such an ILC may include the results from the participating laboratories but would not provide information on the performance of each laboratory.&nbsp;</li><li>Participating laboratories may be required to assess multiple samples and/or to undertake multiple replicate analysis on the candidate reference materials. Thus this may not be representative of the routine measurements or tests undertaken by the laboratory.&nbsp;</li></ul><h4><strong>Other ILCs&nbsp;</strong></h4><p>Some other ILCs, whilst not being conducted in full compliance of the requirements of ISO/IEC 17043, may be designed to evaluate participant performance. These would include small ILCs as defined by EA‑2/21 [5] or split sample ILCs i.e. where a portion of a single sample is sent to two or three laboratories. Whilst these ILCs are specifically designed to evaluate participant performance, they may not provide a comprehensive comparison that a PT might provide. In such cases the laboratory needs to evaluate carefully the competence of the organization managing the ILC and the suitability of the service externally provided (ISO/IEC 17025 clause 6.6).</p>

Interlaboratory comparisons other than proficiency testing

Article

Webinars

Academy

A unique company dedicated to serving science helping our customers drive productivity and accelerate results. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services.

Thermo Fisher Scientific

Eurachem is a European network promoting international traceability of chemical measurements and good analytical practice. It provides expert guidance, supports method validation, uncertainty evaluation, proficiency testing, and facilitates discussion on technical and policy issues in analytical quality.

Eurachem

Everything from the world of analytical chemistry in one place. We connect people in solving their problems. At Labrulez you will find all the necessary information easily, quickly and clearly. Stop searching and start finding.

LabRulez

The Analytical Scientist

Agilent Technologies

Technology Networks

SCIEX

Waters Corporation

<p><strong>Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.</strong></p>
<p>In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing.  This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.</p>
<blockquote>
<p><strong>Presenter:</strong> Blaine Roberts, PhD (Associate Professor, Department of Biochemistry and Department of Neurology, Emory University)</p>
</blockquote>
<blockquote>
<p>Dr. Blaine Roberts is an Associate Professor In the Department of Biochemistry and Department of Neurology at Emory University. He obtained his Bachelor of Science in Chemistry at Montana State University and his PhD in Biochemistry and Biophysics from Oregon State University. His research group focuses on using protein biochemistry and mass spectrometry to understand Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis. He has interest in understanding the role of metals in biology and has developed new proteomic technologies to measure metalloproteins. Further, his group is using proteomics to characterize new blood borne biomarkers for Alzheimer’s and Parkinson’s disease.</p>
</blockquote>


Agilent Technologies: The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays

The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays

The Hidden Pathophysiology of Lipids and Proteins in Alzheimer’s Revealed with Ion Mobility MS and Quantitative QQQ Biomarker Assays.

Pathophysiology of Lipids and Proteins in Alzheimer’s

<p><strong>Ion Mobility (IM) advancements in Software, Data Bases, AI and Machine learning are quickly improving capabilities to make unknown identifications, separate and ID isomers, as well as improve workflows associated with metabolomics, lipidomics, PFAS, and qual-quant screening.</strong></p>
<p>In addition, IM measurements are significantly improved with HRdm High Resolution Demultiplexing.  This is the first commercial IM instrument to enable the simultaneous combination of high drift resolution, while at the same time achieving all four of the following measurement capabilities: broad mass range in a single injection, multiplexing to increase sensitivity, compatibility with fast chromatographic acquisition rates , and highest precision in CCS measurements. For more accurate CCS predictions, the better precision in the CCS training set improves AI machine learning SW. This can significantly reduce the number of potential candidate structures to select from when making unknown identifications.</p>
<blockquote>
<p><strong>Presenter:</strong> Brock Juliano (Ph.D. student, Brandon Ruotolo lab, Dept of Chemistry, Univ of Michigan)</p>
</blockquote>


Agilent Technologies: Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening of Protein and Oligonucleotide Biotherapeutics.

Development of RapidFire Native Mass Spectrometry and Collision Induced Unfolding Methodologies for High Throughput Screening.

RapidFire Native MS of Proteins and Oligonucleotides

<p><strong>Welcome to The Analytical Scientist’s Trends and Challenges in PFAS Analysis forum!</strong></p>
<p>Per- and poly-fluorinated alkyl substances, or PFAS, are a family of synthetic substances used in everyday products, such as stain and grease-repellent coatings and have appeared in almost all foods and drinking water. Toxic at extremely low levels, regulators demand low detection limits, and the list of PFAS compounds under investigation continues to expand. </p>
<p>We recently asked our readers for their thoughts on the challenges involved in PFAS analysis, whether current methods are up to the task, and what analytical advances may be on the horizon. </p>
<p>Here, our panel of experts will discuss the survey findings and share their perspectives on the latest trends and best practices in PFAS analysis. </p>
<p>The event will have three parts: </p>
<ul>
<li><p><strong>Part I: A discussion of the results of our recent vendor-neutral audience survey (10-15 minutes).</strong></p>
</li>
<li><p><strong>Part II: Technology/application-focused presentations from each of our speakers (15 minutes each).</strong></p>
</li>
<li><p><strong>Part III: A chance for you to ask our speakers questions as part of an audience Q&amp;A (15 minutes).</strong></p>
</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Day Powell (Environmental Application Specialist , Agilent)</p>
</blockquote>
<blockquote>
<p>Day has worked for Agilent as an Environmental Specialist for one year. Before this he worked for a major UK Water company (United Utilities) as a senior analyst responsible for developing new methodologies for both LC/MS and GC/MS applications.</p>
</blockquote>
<blockquote>
<p>Day has analysed PFAS for several years and helped United Utilities to gain UKAS accreditation for determining 47 PFAS by LC/MS in drinking water using direct injection to address the latest Drinking Water Inspectorate (DWI).</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Marcus Chadha (EMEA Applications Specialist Manager, Agilent)<br/>Dr. Marcus Chadha has worked for Agilent for seven years where he first worked as an LC/MS Field Application Specialist before moving on to being the EMEA Applications Specialist Manager in 2021.</p>
</blockquote>
<blockquote>
<p>In his roles he has collaborated with our Environmental and Food customers, developed new methods, and trained LC/TQ and LC-Q/TOF MS workflows to new and existing customers.</p>
</blockquote>
<blockquote>
<p>He now coordinates these activities using his team of GC/MS and LC/MS application specialists. Marcus is also responsible for the market specialisation activities for the environmental market across Europe.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Linx Waclaski (Product Manager for Ion Chromatography, Metrohm USA)</p>
</blockquote>
<blockquote>
<p>Linx Waclaski is the Product Manager for Ion Chromatography at Metrohm USA, in Riverview, Florida. He has years of experience in multiple chromatographic techniques, including ion chromatography, gas chromatography, liquid chromatography, and mass spectrometry, with extensive experience in R&amp;D and applications development.</p>
</blockquote>
<blockquote>
<p>His chromatography applications experience extends across environmental, food safety, and life sciences industries. He has an M.S. in Forensic Science from Duquesne University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ruth Marfil-Vega (Senior Market Manager - Environmental, Shimadzu)</p>
</blockquote>
<blockquote>
<p>Dr. Ruth Marfil-Vega has 20 years of expertise in environmental chemistry and engineering in the US and Europe. She has worked with the EPA and the utilities industry to design and execute comprehensive solutions for addressing new environmental and water quality issues, including PFAS, regulated and unregulated DBPs, and other emerging contaminants.</p>
</blockquote>
<blockquote>
<p>Since Ruth joined Shimadzu five years ago, she has continued to work with environmental stakeholders to ensure that analytical instrumentation and workflows support their success.</p>
</blockquote>
<blockquote>
<p>She earned a BSc in Chemistry from the University of Valladolid (Spain) and a PhD in Environmental Science and Engineering from the University of Cincinnati.</p>
</blockquote>


Agilent Technologies: Trends and Challenges in PFAS Analysis

Trends and Challenges in PFAS Analysis

Survey findings and perspectives on the latest trends and best practices in PFAS analysis.

<p><strong>This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.</strong></p>
<p>This online symposium will explore:</p>
<ul>
<li><strong>Cutting-edge proteomics for brain aging and dementia biomarkers</strong></li>
<li><strong>Innovations in single-cell proteomics technology</strong></li>
<li><strong>Next-gen protein sequencing and PTM detection</strong></li>
<li><strong>Healthcare transformation through data analytics and remote monitoring</strong></li>
</ul>
<h3><strong>Agenda</strong></h3>
<h5><strong>16:00 – 16:40 (BST) Keynote: Transforming Healthcare Using Deep Data and Remote Monitoring</strong></h5>
<ul>
<li>Keynote Speaker: Prof. Michael Snyder</li>
</ul>
<h5>16:40 – 16:50 Networking Break</h5>
<h5><strong>16:50 – 17:35 Challenges In Human Metabolomics Studies and Standardizing Quantitative Metabolomics Globally</strong></h5>
<ul>
<li>Speakers: Prof. Jerzy Adamski &amp; Markus Langsdorf, PhD</li>
</ul>
<h5>17:35 – 17:45 Networking Break</h5>
<h5><strong>17:45 – 18:35 Proteomics as a Tool to Identify Drivers and Biomarkers of Brain Aging and Dementia</strong></h5>
<ul>
<li>Speaker: Keenan Walker, PhD</li>
</ul>
<h5>18:35 – 18:45 Networking Break</h5>
<h5><strong>18:45 – 19:05 Advancing Protein Analysis with Next-Generation Protein Sequencing™</strong></h5>
<ul>
<li>Speaker: Ben Moree, PhD</li>
</ul>
<h5>19:05 – 19:15 Networking Break</h5>
<h5><strong>19:15 – 20:05 Improved Sample Preparation, Separations and Data Acquisition for Single-Cell Proteomics</strong></h5>
<ul>
<li>Speaker: Ryan Kelly, PhD</li>
</ul>
<h5>20:05 – 20:15 Networking Break</h5>
<h5><strong>20:15 – 20:55 Identification and Analysis of Non-Invasive Biomarkers in Exhaled Breath</strong></h5>
<ul>
<li>Speaker: Tina Chou, PhD</li>
</ul>


Technology Networks: Advances in Proteomics & Metabolomics 2023

Advances in Proteomics & Metabolomics 2023 - Day1

Areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.

<p><strong>This popular online event will once again bring together leading scientists in the field as they highlight the latest advancements in translational proteomics and metabolomics. Presentations will cover areas ranging from uncovering the molecular mechanisms of disease pathology, to the latest technological developments in diagnostics and treatment.</strong></p>
<p>This online symposium will explore:</p>
<ul>
<li><strong>Cutting-edge proteomics for brain aging and dementia biomarkers</strong></li>
<li><strong>Innovations in single-cell proteomics technology</strong></li>
<li><strong>Next-gen protein sequencing and PTM detection</strong></li>
<li><strong>Healthcare transformation through data analytics and remote monitoring</strong></li>
</ul>
<h3><strong>Agenda</strong></h3>
<h5><strong>16:00 – 16:40 Deciphering Microbial Omics Signatures in Multidimensional Mass Spectrometry</strong></h5>
<ul>
<li>Speaker: Aivett Bilbao, PhD</li>
</ul>
<h5>16:40 – 16:50 Networking Break</h5>
<h5><strong>16:50 – 17:10 Precision Proteomics Accelerates the Early Detection of Dementia</strong></h5>
<ul>
<li>Speaker: Mariana Fontes, PhD</li>
</ul>
<h5>17:10 – 17:20 Networking Break</h5>
<h5><strong>17:20 – 18:10 Towards the Making of Molecular Movies Directed by the Circulating Proteome</strong></h5>
<ul>
<li>Speaker: Prof. Jochen Schwenk</li>
</ul>
<h5>18:10 – 18:20 Networking Break</h5>
<h5><strong>18:20 – 18:40 Lipidomic Variabilities of Human Blood Plasma</strong></h5>
<ul>
<li>Speaker: Prof. Markus Wenk</li>
</ul>
<h5>18:40 – 18:50 Networking Break</h5>
<h5><strong>18:50 – 19:30 The SEISMIC Facility for Spatially Resolved Single and Sub-Cellular Omics</strong></h5>
<ul>
<li>Speaker: Prof. Melanie Bailey</li>
</ul>


Advances in Proteomics & Metabolomics 2023 - Day 2

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces. MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</strong></p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</p>
<h3><strong>Part Two – October 17th, 2023: Untargeted versus Targeted Imaging</strong></h3>
<p>In the second session, we will look at the differences between untargeted and targeted imaging: the systems on which the data can be acquired, what data is collected using each technique, how data can be analyzed and how they can work together to provide a complete picture.</p>
<blockquote>
<p><strong>Presenter:</strong> Anthony Midley (Principal Applications Support Scientist, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Anthony Midey is a Principal Applications Support Scientist in Waters Biomedical Research group at Americas Application Laboratory, providing pre- and post-sales support in DESI, MALDI, and imaging mass spectrometry. He is also the BMR team lead for targeted metabolomics and lipidomics LC-MSMS applications. Anthony received his Ph.D. in spectroscopy and mass spectrometry from the University of Rochester and joined Waters in 2015. He has over 55 publications in peer-reviewed journals, with over 10 years working in the analytical instruments sector.</p>
</blockquote>
<blockquote>
<p><strong>HOST:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: Untargeted versus Targeted Imaging

Untargeted versus Targeted Imaging

We will look at the differences between untargeted and targeted MS imaging.

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces. MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</strong></p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</p>
<h3><strong>Part One – October 10th, 2023: What is mass spectrometric imaging?</strong></h3>
<p>In this session, we will examine the types of MS imaging techniques on the market and the platforms on which they can be run. We will also discuss the types of data and information that MS imaging can provide and what imaging provides a user that other mass spectrometric techniques cannot.</p>
<blockquote>
<p><strong>Presenter:</strong>  Bindesh Shrestha (Senior Application Support Scientist, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Bindesh Shrestha, PhD., is an expert in the field of imaging mass spectrometry and ambient ionization. He completed his graduate work at the George Washington University and is currently employed with the Waters Corporation. In Waters, Bindesh supports academic grant efforts with biomedical applications, such as imaging MS and metabolomics. Bindesh has co-authored about three dozen peer-reviewed articles in leading journals, such as Angewandte Chemie, Analytical Chemistry, Analyst, Nature Methods. In the last two years, he edited a book on single-cell metabolism with Springer and published an introductory book on imaging mass spectrometry with Elsevier.</p>
</blockquote>
<blockquote>
<p><strong>HOST:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: What is Mass Spectrometry Imaging?

What is Mass Spectrometry Imaging?

We will examine the types of MS imaging techniques on the market and the platforms on which they can be run.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 1: Wednesday, October 25</h3>
<h5><strong>10:00 - 10:40 The Echo® MS system, a high throughout mass spectrometry, Revolution to accelerate hit finding and drug discovery</strong></h5>
<ul>
<li>Celine Legros and Dany Jeanne Dit Fouque (Eurofins)</li>
</ul>
<h5><strong>10:40 - 11:20 Qualification of lipid biomarker assays using chromatography with triple-quad mass spectrometry</strong></h5>
<ul>
<li>Freddy Oosterbring (Ardena)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Mass spectrometry, a useful aid in Alzheimer´s disease diagnosis</strong></h5>
<ul>
<li>Jose Antonio Allué (Araclon)</li>
</ul>
<h5><strong>12:10 - 12:50 LC-MS to analyze oligonucleotides: a tool for the characterization of new biotherapeutics</strong></h5>
<ul>
<li>Margalida Artigues (IQS)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 1)

Interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work.

<p><strong>Are you ready to propel drug development and revolutionize the pharma industry?</strong></p>
<p>On the quest to develop more effective drugs, the synergy between technology providers and scientists is paramount. Together, they generate reliable and reproducible results, accelerating new chemical entities through the pipeline. From research to commercialization, a continuous cycle of tests and workflows shapes the future, determining your success.</p>
<p>Discover new possibilities:</p>
<p>Unlock the potential of cutting-edge technology and master the art of making the right decisions. The 2-day event brings you interactive expert talks, enriching your knowledge and empowering you to embrace innovative techniques that save precious time at work. From the research of new markers to the drug development moving into non and GLP bioanalysis. Plan your next lab expansion with confidence.</p>
<p>Why attend?</p>
<ul>
<li><p><strong>Insightful expert talks: engage with 8 prominent speakers and key opinion leaders in the field</strong></p>
</li>
<li><p><strong>Explore mass spectrometry in pharma: talks about research and quantitation of biomarkers, characterization of metabolites, drug quantitation and nitrosamine impurities, harness the power of mass spectrometry and plan your lab expansion with confidence</strong></p>
</li>
<li><p><strong>Collaboration and networking: connect with like-minded professionals, share experiences, and build valuable connections within the industry</strong></p>
</li>
<li><p><strong>Be the forefront of advancements: stay ahead of the competition by gaining insights into the latest trends and advancements in pharma technology</strong></p>
</li>
</ul>
<h3>Agenda Day 2: Thursday, October 26</h3>
<h5><strong>10:00 - 10:40 Case studies from bioanalytical lab in DMPK, Syngene: SCIEX 7500 system and beyond</strong></h5>
<ul>
<li>Ashwani Gaur (Syngene International Ltd)</li>
</ul>
<h5><strong>10:40 - 11:20 Challenges in quantification of NDSRI’s</strong></h5>
<ul>
<li>Dama Venugopal Rao (Dr. Reddy&#39;s Laboratories)</li>
</ul>
<h5><strong>11:20 - 11:30</strong> Break</h5>
<h5><strong>11:30 - 12:10 Nitrosamine impurities in dermal products: from APIs and their salts (secondary amines) evaluations through analytical chemistry and mass spectrometry</strong></h5>
<ul>
<li>Emiliano de Dominicis (Merieux)</li>
</ul>
<h5><strong>12:10 - 12:50 Extractables and leachables assessments in biologics manufacturing</strong></h5>
<ul>
<li>Lukas Mogler (Lonza)</li>
</ul>
<h5><strong>12:50 - 13:00 Final notes</strong></h5>
<ul>
<li>Ferran Sanchez (SCIEX)</li>
</ul>
<blockquote>
<p><strong>Presenter:</strong> Celine Legros (Drug Discovery, Partnership Director, Eurofins Discovery)</p>
</blockquote>
<blockquote>
<p>Celine Legros, PhD, Drug Discovery Partnership Director, is deeply involved in the design of complex projects, including Hit-Finding, Hit-toLead and Lead-Op programs. Prior to joining Eurofins, Dr. Legros was Scientific Project Leader in the Screening Department at the Institut de Recherches Servier, France, where she was involved in neuroscience, cardio-metabolic diseases, immune-inflammation, and oncology projects, from HTS through to Lead-Optimization. Dr. Legros holds a Ph.D. in Animal Physiology (melatonin circanual rhythm and melatonin receptors) from the University of Tours, France, and completed a postdoctoral fellowship at the Blood Brain Barrier Group at King’s College London, UK.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Dany Jeanne Dit Fouque (Development Analytic Engineer, Eurofins Cerep)</p>
</blockquote>
<blockquote>
<p>Dany Jeanne dit Fouque, PhD, is a Mass Spectrometry Analytical Development Engineer at Eurofins Cerep. He has 7 years of experience in analytical chemistry with in-depth knowledge in UHPLC-MS/MS method development, enzymatic reaction and MS-Binding using mass spectrometry. Prior to joining Eurofins, he worked in the academic sector on several R&amp;D projects to develop and optimize a new methodology using UHPLC-MSn experiments to identify and quantify isomeric/isobaric compounds in mixture. Dr. Jeanne dit Fouque received his Ph.D. in Mass Spectrometry from the University of Brest, France.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Freddy Oosterbring (Senior Scientist, Deputy Director Laboratory, Ardena)</p>
</blockquote>
<blockquote>
<p>Freddy Oostebring, Manager Laboratory section chromatography and mass spectrometry at Ardena Bioanalysis. He holds a bachelor degree in Analytical Chemistry and has been working with triple quad mass spectrometry for more than 20 years. His expertise is in the field of method development for the analysis of small molecules, targeted lipids and peptides in biological matrices. Since 2019, he has been a member of the SCIEX Innovation Advisory Board.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Jose Antonio Allué (Senior Scientist Mass Spectrometry Laboratory, R&amp;D Department, Araclon Biotech S.L., Ph.D. (Pharmacy) University of Barcelona, Spain.)</p>
</blockquote>
<blockquote>
<p>Twenty-five years in the field of Biological Mass Spectrometry, fifteen of them dedicated to research in Alzheimer´s Disease by HPLC-MS/MS (MALDI, IMS-MS, Orbitrap-MS, reTOF-MS, TOF/TOF-MS, Ion-Trap-MS and Triple Quadrupole-MS). Applications of both, targeted and untargeted, proteomic techniques in the fields of immunology, metabolism, pharmacokinetics and pharmacodynamics. Applications of High-Mass MALDI Mass Spectrometry for the analysis of protein complexes and vaccines. Label-free shotgun proteomics by Travelling Wave Ion Mobility Spectrometry coupled to TOF-MS. Applications of MS to the study of amyloid species in tissues and biofluids, including human, dog and transgenic mice models. Research focus: blood and cerebrospinal fluid amyloid biomarkers in Alzheimer´s Disease. Direct analysis of amyloid peptides in blood without immunoprecipitation enrichment.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Margalida Artigues (Responsable de IQS SCIEX Demo Lab, Instituto Químico de Sarrià IQS)</p>
</blockquote>
<blockquote>
<p>Margalida Artigues earned her Ph.D. in Chemistry in 2019 from Ramon Llull University. She holds a Master&#39;s degree in Analytical Chemistry, as well as a Bachelor&#39;s degree in Chemistry, both from the same university. Since 2021, she has been leading the Mass Spectrometry Laboratory IQS-SCIEX Demo Lab, based in Barcelona, where she is an integral part of the research team at IQS Tech Transfer. In her current role, her mission is to promote research, facilitate technology transfer, and provide support in educational activities related to the LC-MS analytical technique.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Emiliano de Dominicis (Chemistry Research Director, Mérieux NutriSciences)</p>
</blockquote>
<blockquote>
<p>Emiliano De Dominicis is a researcher with over twenty years of experience in food and pharmaceutical safety, following both private and academic sectors, and he is now Director of Chemical Research - Project Manager at Mérieux NutriSciences. With a Research and Development in Analytical Chemistry dedicated team, Emiliano is responsible for Mérieux NutriSciences Global Research Projects and Scientific Center. Moreover, Emiliano De Dominicis actively participates in funded scientific projects (regional, national and European), scientific congresses as speaker, and writes articles published in specialized scientific journals.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Lukas Mogler (Sr Group Leader, Extractables and Leachables, Lonza DPS)</p>
</blockquote>
<blockquote>
<p>Dr. Lukas Mogler, Sr Group Leader Extractables and Leachables at Lonza DPS Basel Switzerland. He is a graduated diploma pharmacist holding a PhD from University of Freiburg, Germany. Worked in the field of Forensic Toxicology with focus on mass spectrometry and metabolism studies. Joined Lonza DPS in 2020, responsible for extractables and leachables and elemental impurities assessments.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ashwani Gaur (Senior Principal Scientist, Drug Metabolism and Pharmacokinetics, Syngene international Limited)</p>
</blockquote>
<blockquote>
<p>Ashwani Gaur, is Senior Principal scientist in Drug metabolism and Pharmacokinetics department of Syngene international Limited. Ashwani Joined Bioanalytical team in Ranbaxy research Lab soon after completing MS degree in Pharmaceutical Analysis from National Institute of Pharmaceutical Education and Research, India in 2004. Prior to Syngene, he worked in Advinus Therapeutics and Eurofins. Ashwani has contributed to small molecules drug-discovery projects internally and with large and medium size pharmaceutical companies around the globe specifically in lead identification/optimization stages. He leads a team of experts in LC-MS-based bioanalysis of small molecules, metabolites, prodrugs, biomarkers, complex bioanalysis involving chemical derivitisation and exposure determination new modalities like Protacs, ADC`s, oligonucleotides etc. in multiple biological matrices.</p>
</blockquote>


Pharma conclave 2023 (Day 2)

<p><strong>Mass Spectrometry Imaging (MSI) is a technique that allows chemical information to be obtained directly or via the use of matrices from a wide range of surfaces.</strong></p>
<p>MS Imaging provides information on the spatial distribution of molecules at or near the surface. Imaging provides beautiful and information-rich images that allow scientists to answer the fundamental question: “Where is this component in my sample?”</p>
<p>In this webinar series, we will examine the basics of MS imaging, compare the techniques of untargeted and targeted MS Imaging and the information that can be gained from each, and end with an interview from Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) on the practicalities of setting up a MS Imaging Core lab.</p>
<p>Who Should Attend: </p>
<ul>
<li>Any scientist, lab managers or lab directors looking to expand (or refresh) their knowledge of MS Imaging.</li>
</ul>
<h4>Part Three – October 31st, 2023: Building an MS Imaging Facility</h4>
<p><strong>In the final session of the series, we will have a roundtable with Dr. Ryan Leib (Stanford University) and Dr. Roy Martin (Waters Corporation) where we will discuss the steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.</strong></p>
<blockquote>
<p><strong>Presenter:</strong> Roy Martin (Principal Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Dr. LeRoy B. Martin, III is the Principal Field Marketing Manager for Biological Mass Spectrometry at Waters Corporation. His primary role is developing and promoting advanced mass spectrometry solutions in the Americas. He is also charged with evaluating and integrating new technologies and methods in collaborations and product development. Most recently, his focus has been on molecular imaging mass spectrometry and implementation of advances in ion mobility technology. Other research interests include complex mixture quantitative proteomics and structural biology using mass spectrometry. Roy received a BS in Chemistry from Davidson College and a Ph.D. in Analytical Chemistry from North Carolina State University.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Ryan Leib (Director of Research, Stanford University Mass Spectrometry Laboratory)</p>
</blockquote>
<blockquote>
<p>Ryan Leib is Director of Research for the Stanford University Mass Spectrometry Laboratory. Ryan received his B.S. in Biochemistry from the University of Tulsa (Tulsa, OK), with a focus on LC/MS methods development for natural products discovery. In 2010, he received his Ph.D. in Chemistry from the University of California at Berkeley investigating ionic cluster formation and energetics in Professor Evan Williams’ mass spectrometry laboratory. Prior to joining SUMS in 2014, Ryan developed mass spectrometric analyses for complex mixtures as a Project Leader at SRI International, a non-profit contract R&amp;D firm based in Silicon Valley.</p>
</blockquote>
<blockquote>
<p><strong>Presenter:</strong> Kieron Faherty, Ph.D. (Separations and Mass Spectrometry Field Marketing Manager, Waters Corporation)</p>
</blockquote>
<blockquote>
<p>Kieron Faherty is the Separations and Mass Spectrometry Field Marketing Manager for the Americas at Waters Corporation. He received his B.Sc. (Hons) in Chemistry from the University of Reading (Reading, Berkshire, UK) and his doctorate in Chemistry from the University of Massachusetts (Amherst, MA). He has held several field-based positions at Waters, most recently as a Field Applications Specialist focused on biopharmaceutical applications using Time-of-Flight mass spectrometry instrumentation.</p>
</blockquote>


Waters Corporation: Building an MS Imaging Facility

Building an MS Imaging Facility

The steps necessary to set up an MS imaging core lab and answer questions such as: “who runs this type of lab?” and “who are the main customers?”.

LCMS webinars focusing on LC/TOF - page 23